Clinical Trials - September 25, 2016
AstraZeneca announces 2 new trials
AstraZeneca has announced two new randomised, placebo-controlled Phase IIIb outcome trials with Forxiga (dapagliflozin), an SGLT-2 inhibitor currently indicated for the treatment of type-2 diabetes. These two large outcome trials will help to define the potential role of dapagliflozin in the management of chronic kidney disease and chronic heart failure respectively, in people with and […]
Clinical Trials - September 9, 2016
AZ shows positive phase III trials
Results from pivotal Phase III trials presented at the European Respiratory Society International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype. The SIROCCO and CALIMA trials evaluated the effect of two dosing regimens of benralizumab 30mg administered […]
Acquisition - August 25, 2016
AZ sells antibiotics business to Pfizer
AstraZeneca has announced that it has entered into an agreement with Pfizer to sell the commercialisation and development rights to its late-stage small molecule antibiotics business in most markets globally outside the US. Under the terms of the agreement, Pfizer will make an upfront payment to AstraZeneca of $550 million upon completion and a further […]
Uncategorized - August 24, 2016
Genes responsible for heart attack identified
Thousands of genes and their interactions across tissues mediating cardiometabolic diseases have been identified. The research, published in Science , is a result of a joint collaboration between the Icahn School of Medicine at Mount Sinai, Tartu University Hospital in Estonia, Karolinska Institutet and Science for Life Laboratory (SciLifeLab) in Sweden, and AstraZeneca. The identified […]
Drug Development Pharma - August 23, 2016
AZ, Lilly receive fast track designation
AstraZeneca and Eli Lilly and Company have received US Food and Drug Administration (FDA) Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial. The FDA’s Fast Track programme is designed to expedite the development and review of new […]
Clinical Trials - August 16, 2016
AZ update Selumetinib trial
AstraZeneca has announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). The results showed that the trial did not meet its primary endpoint of progression-free survival (PFS), and selumetinib […]
